NAPISTAR-301

APGOT-OV22: Open-label, randomized (1:1) phase III study to investigate TUB-040 monotherapy when compared to physician’s choice of therapy in patients with high-grade, serous or endometrioid platinum-resistant ovarian cancer (PROC).

NAPISTAR-3012026-09-16T16:24:01+10:00

BEHOLD-En01 | NCT07286331

APGOT-EN4: A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy.

BEHOLD-En01 | NCT072863312026-09-16T16:15:45+10:00

Starstone OV301

APGOT-OV29: A Phase 3, Open-label, Multicenter, Randomized Study of BG-C9074 With Bevacizumab Versus Bevacizumab as First-line Maintenance Therapy for Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After First-line Platinum-based Chemotherapy Plus Bevacizumab.

Starstone OV3012026-09-16T16:04:48+10:00

RAINFOL-10

APGOT-OV30: A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Bevacizumab Versus Bevacizumab as Maintenance Treatment Following First-Line (1L) Platinum-Based Chemotherapy Plus Bevacizumab in Participants Without Known Homologous Recombination Deficiency (HRD)-Positive Ovarian Cancer.

RAINFOL-102026-09-16T16:00:05+10:00

RAINFOL-08 | NCT07564141

APGOT-EN7: A Phase 3 Randomized, Open-Label Study of Rinatabart Sesutecan (Rina-S) Plus Pembrolizumab versus Chemotherapy Plus Pembrolizumab for 1L Treatment of Patients with Primary Advanced or Recurrent pMMR Endometrial Cancer.

RAINFOL-08 | NCT075641412026-10-01T12:49:55+10:00

RAINFOL-03 | NCT07166094

APGOT-EN3: A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Endometrial Cancer (EC) After Platinum-Based Chemotherapy and PD(L)-1 Therapy.

RAINFOL-03 | NCT071660942026-09-16T15:56:28+10:00
Go to Top